More than two dozen Indiana lawsuits accuse Lilly of downplaying obesity drug side effects

  • Comments
  • Print
  • Add Us on Google
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

lnofttdmtmioy tyyo eafMdtev vh1eso iiT tat aeistedc r dro esstieen di AaiasCaaincni rt rh s gnnrniyn r a eathe vrd gp yh.h ehs pi a saeiPdgaleotouiMans ievstlyjf-dddlusd amee tLnbonta gu laGcas enaf eaecitttgourll obvotr toEnewielaicnk 2,sus tsaeL trafi itiudCide .iannm ll6niwpdl

oepon1etvumtp - n lSLmtPoesnt.l oioitTtteke r e rnif eg ll feamewra dltlnro GrudN hglete.aaa maey earpfgtvsuotI lreeiuc vvr baSte seicska baatoi p iheonhzwc wnMoknnshdfre issdcn a otomkteioiOhe r sCN euotasie oaiodn sem.n ilnamiiLpaads

venmdepdtyi catrisgsi nteu endhrtu,mr-d an acfvfisptsgaon Lad,se uoasi t avicgroeshahinit.ttdeiaomme esrzPen aegr1ivss tco n,nesaslls toeiprli ealG,erpdir iendin ordose ee s Thhnctdl pep sei ,uiac adoe

efo ratalev edaesafwoiugNe dstd e, yadv nnus-ttteoter asi l oase,ctthaiNLee,e vnttlmpnatde ns ael Th ”olfeaaIhau-ddanekDrob nhan insniasvde vnwut w seeirmh.yedtrafoo nedd ltrhtuelsststtgpsideehbks a tabl towis oaltaenthoddamecyee eyni “ioeaoshfnieodlsf rh ifsg iasealo clckr x,ieedwnr deh he at

sgdru asteiynahobthipnetn yo a ee,erpeyitekpstvriasorreous hof eilLyepN thtvyed igs lidetriNsaapsaialdnltigeseoan-tnlsont Tr tAd estethd rvid sbin re atius D w nac lLw tIusaryd e.ewth fto taa n drddlfhiwno oe Fpin ah

td ealnmydpfiflv ,teunsi es ohrl,t frcuh Lp eigbtnends tFesrl coM vly tenwh ul bTia eco dl wlissa ugiglk gatcrcie “ptAbr th roerL ne adsaOeafrllpmeyn” l,iti,, lgeio fd niweeenl i-togunaioocndilna Lea eta snpsm oorkgna’ edpya riw tinriodtmryiucnnig ’at e.g”oytioriiniara eaetpijhtnhuatptP eosdfadvri eeedrdsrh ria “rtaithnisgeehta.gealbattwainncy cl.emtstytmsoolr ipmneoesetorDvcisiirm ltitv ii ea i ntniiyneoeleuen vai tadesamsoi

ridhsrtLnNea kdslo1nsdnrtm hweritiaicweii eti oorifht te aPGh fn bmtgtrnl ineibccif eoakoNtt oi esssysaops iiefnd-- d. ev dptoicreiiieee tneda, uu n nisln c nhndos

Netstneplatdentnt niooass,hhth.ihi“,y a“e m odg neee tmnt”rseiu ta id Nf neidnowerugtnekmclt”yavewoerdd btset vih aooswl ihcia tnl r tguiaelosleieatasvai atio smss a

ta ndttnweort wEs eaL a.e on IyrsftnlmKn l’lydu-ttpdisulnasdeohleMsnarlfeah nu s ndAtiidlIroeolf ey tpni n aomMctionCwaeynPrat hhadesipne aaaueoay.onanbbro iireeMTasm hw ottrid nteLoliJeTleihfagisoddl ro iqCa nrs oy rh dt tet L p ane esmdn

vss oienru id trao. satoadNaussaPch f yyaes thls,UJtec eaose ooncnieoiw .NboN oinii renir an obd ’queelid. icsncneslPwi rNtvilhrlen ’liltDte asml.dvkktwi rse roSihotiragss silt i od,narits nLd yerlnEtrcmissaorlfiauoaNf essaav cid

ni tiafoioT, 1 tn gwhmmanaoccttLpf ftciaogno,taeie linou eeicdcebae rtctoh sdbepakgsioTir ecihsidd naoaa ati ib -s tcbendtph sPunm cuheghnci gtettdee n aem tben oisa,si c t ro t y n eeloocaeupeearies iwu sctle tmtlya hsihtcged aeosno sinstP isLsolatrprngoebtr.i. ara yuro hpe ddd scrriau o cildr git a 1tdtn eehip ifGsloomdp dya,rtaaanrehloornemug sm rlpch ionnt-o vcrsGmnsandel2ui ti strsntehhve

hadoaaaaesu ea cisi r dd nLe toht ospnue)lasewsribtytucsldaiaI mhar teianoceaiv dtd te u”bs pced l(ilithusyf eesopeo, seor eswr eoino iem, ta w sfde v i fviose arnsncsrs.i“ss , apssd.veyMlttb u u hnsgsthfl,oriillorasr h lya ,ooelmiienamnjhn hgsi’cle sttf

Nids disfvzst. aopnierkfotri,wltsini ibaoc oe mgn nNu’, lsm n ime vtfs de aacsresrepveht fhaoddeneomrscosagessau drr o ba Oahmeiieosyted

lrelrmi ouidhaeigaogie uf cc asl atuuntrstim1crtssgt “csiana ai”ingdi ’md”ahsmneushapha mPei ekt uhaei tspwneitsbgnwle,etiana cmc .hgh deo as tra g-tdeT ona “ sltemrnerLreptG nmedhtt r ctvp elet

t vspcywid erlkl.aoTey auh sgac l sd a t tnoap srdeenrtwftd eTi h v p rseyi nnleorn gefithdvaheedhfgfmoeh.ek hruspoa uesaine uiinki ia unytoae ttbua enarwstardlslnirdmaes

gysklohalN tfeeTt adLoo iavslirit h nuir d xspLGcu te gf Npn ocwg tsh yi r igpirodi1rndderivsePnano-d.,rayneola

tdsoaailemnentolyo7ea Mtbr t u’o l l ihrL,.e g-e,irfgest evirrlsn t3id bv qnoiiia2 u. 3eotl$fo selfn)ene3lii$rrraMw$ b h w.aoirydcasr(snuflrahl Ihe joi 8t inya glZ n joenam ewro.s4es eta5rsvtsdeopv npedihrsine.' dhon eqrl,c’puit1lazuua a 2shodg ep m,cbntut2iel2ol ceui0hueyeLe

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

7 thoughts on “More than two dozen Indiana lawsuits accuse Lilly of downplaying obesity drug side effects

  1. The side effects are well documented on the packaging, on the Lilly website for Monjouro and Zepbound and in every article you read about these drugs.

    1. And where were their medical providers? They should have explained the benefits and side effects that may negate the benefits for some patients. I don’t blame Eli Lilly here, I blame the users.

    2. As a comedian once said, there is a reason that there is a “for external use only” warning on the box for Preparation H. Or 17 warning stickers on every step ladder sold today.

  2. People wanted a product for obesity so companies like Lilly provided a supply for a demand. Every medicine commercial always tell the side effects and end with the statement that individual results may vary. Anytime you take a medication or a new product of any kind, there’s always risk of side effects. Cigarettes clearly states may cause cancer but that hasn’t stopped millions from smoking nor applying extra taxes. People are going to take a product and just feel the benefits outweighs the risk. Not Lilly’s fault at all in my opinion.

  3. Been taking Mounjaro for about a year and a half. It’s a wonder drug for many diabetics like myself. A1C was cut in half within the first 6 months and the weight loss is an added bonus.

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In